DENVER, COLORADO — February 15, 2012 — Corgenix Medical Corporation (OTCBB:CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today its second generation Hyaluronic Acid (HA) Immmunoturbidimetric Test Kit for use on automated chemistry analyzers has received CE marking for commercialization in Europe. The new product is the second Corgenix product for measuring blood levels of hyaluronic acid to assess the degree of liver fibrosis and cirrhosis in chronic liver disease. The first Corgenix product is configured as an ELISA microplate and has been commercialized worldwide since 1998.  

“The CE marking of our automated HA product reaffirms our market leadership position in non-invasive biomarkers for assessing chronic liver disease and allows us to commercialize the product in Europe through our distribution partner ELITech,” said Corgenix President and CEO Douglass Simpson. “We have a very active development program with ELITech and over the next few years will be bringing additional new and exciting products to the world markets.” 

In 2010 Corgenix and ELITech entered into the Joint Product Development Agreement, a strategic alliance to co-develop new diagnostic tests. The automated HA product was the first product released as a result of that collaboration. It is now available worldwide, including Europe, through ELITech; in the U.S. it will be available for research purposes only through Corgenix. 

In all countries where the use of this product has not been cleared by local regulating agencies, the product shall not be used for diagnostic purposes. None of the Corgenix Hyaluronic Acid products are FDA cleared for diagnostic use in the U.S. 

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com

 About the ELITech Group

The ELITech Group is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITech Group has become a major contributor in advancing clinical diagnostics to laboratories in the  proximity market, those operating closer to the patient. The ELITech Group manufactures and distributes diagnostic products for clinical chemistry, microbiology, immunology, and molecular biology though direct sales and a distribution network encompassing more than 100 countries. More information is available at www.elitechgroup.com

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.

William Critchfield, Senior VP Operations and Finance and CFO

Phone: 303-453-8903

Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing

Dan Snyders, Vice President and Public Relations Supervisor

Phone: 303-623-1190 x230

Email: dan@armadamedical.com

DENVER –February 14, 2012 – Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:

• Revenues for the quarter increased $279,691 or 15.7% vs. the prior year’s comparable quarter
• Revenues for the six months increased $479,675 or 12.7%  vs. the prior year’s comparable six months
• Interest expense decreased $17,227 or 37.4% vs. the prior year’s comparable quarter

“In this latest reporting period, we continued the double-digit revenue growth seen in recent quarters,” stated Douglass Simpson, Corgenix CEO and President. “It is especially encouraging that most of the increase came from the newer and more profitable products like AspirinWorks and Hyaluronic Acid. Likewise, our Contract Manufacturing sector increased over 200% this quarter, a trend we expect will continue through the rest of this year and into Fiscal 2013.”

The company further noted that the financial performance for the quarter was not as strong as expected, with some weakness in international and certain core product revenue. The company continues to believe that the third and fourth fiscal quarters will be considerably stronger and that Fiscal Year 2012 revenues will set a record for the Company’s annual revenues, currently expected to be approximately $9.7 million, with concurrent improvements in net income and adjusted EBITDA versus the prior year. As is always the case, there can be no such assurance that these results will be realized.

Second Quarter 2012 Conference Call Details

Corgenix invites all those interested in hearing management’s discussion of second quarter results to join a shareholders conference call on Tuesday, February 14, 2012, at 4:00 p.m. EST (2:00 p.m. MST). Interested parties can join the call by dialing (800) 894-5910. International participants may access the call by dialing +1 785 424 1052. The conference code is “CORGENIX.” A replay will be available for 30 days following the call by dialing (800) 723-2156 for U.S. participants and +1 402 220 2660 for international participants. 

 About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SUMMARY OF FINANCIAL HIGHLIGHTS

($000 of U.S. dollars except shares outstanding and per-share amounts)

CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES OPERATIONAL DATA

The goal of the Consortium is to understand mechanisms related to the human immune response to Lassa virus infection. Specifically, by understanding what parts of the virus are recognized by the immune system, we can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa Fever.

Tulane’s previous efforts focused on the development of new recombinant proteins for Lassa virus and diagnostic products, which have shown to be extremely effective in clinical settings in Africa. The new NIH award enables research to move to the next level, allowing for focus to be shifted towards better treatment and ultimately prevention of Lassa fever altogether.

The Consortium is a collaboration between Tulane, Scripps Research Institute, Broad Institute, Harvard University, University of California at San Diego, University of Texas Medical Branch, Autoimmune Technologies LLC, Corgenix Medical Corporation, Kenema Government Hospital (Sierra Leone), Irrua Specialist Teaching Hospital (Nigeria) and various other partners in West Africa. Together they work on evaluating antibodies from patients who have been infected by Lassa virus and have subsequently recovered, to see if those antibodies might play a role in the development of a vaccine or treatment for the illness. The Consortium intends to expand this program to include other important infectious agents such as Ebola, Marburg and other Arenaviruses that are of great concern to public health and bioterrorism. More information is available at www.vfhc.org.

Corgenix and ELITech collaborate on product development and product sales. ELITech is the exclusive master distributor for commercializing Corgenix products outside of North America.

Corgenix manufactures the BG Medicine Galectin-3 ELISA product, an in-vitro diagnostic product used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

Corgenix and AXA work together in laboratory instrumentation. Corgenix distributes the SkyLab 752 system manufactured by AXA.

Corgenix and Randox are collaborating on the application of some of the Corgenix products to Randox delivery platforms.

Corgenix and Zalgen members of the Viral Hemorrhagic fever Consortium, working to develop state of the art diagnostic products for biothreat agents and emerging pathogens.

Corgenix and Tulane are members of the Viral Hemorrhagic fever Consortium, working to develop state of the art diagnostic products for biothreat agents and emerging pathogens.

Corgenix and USAMRIID are members of the Viral Hemorrhagic fever Consortium, working to develop state of the art diagnostic products for biothreat agents and emerging pathogens.